Twelve-Month Persistency with Oral 5-Aminosalicylic Acid Therapy for Ulcerative Colitis: Results from a Large Pharmacy Prescriptions Database
- 327 Downloads
Patients receiving 5-aminosalicylic acid (5-ASA) require long-term therapy to achieve good outcomes. Persistency (duration of time from initiation to discontinuation of therapy) is therefore an important consideration.
To evaluate persistency in patients receiving various oral 5-ASA formulations.
This retrospective, 12-month, cohort study examined new-starter patients (any age and diagnosis) from a large United States pharmacy database who filled a prescription for oral 5-ASA [Lialda®, Asacol®, Pentasa® 250 or 500 mg, balsalazide (generic and Colazal®), and olsalazine (Dipentum®)] between March and September 2007. Persistency was evaluated monthly on the basis of prescription refill rates.
Prescription and refill records were identified for 44,191 patients receiving oral 5-ASA. After 1 year, 20% of patients receiving Lialda were considered persistent and classified as continuing (refilling within a timeframe of up to twice the duration of the prescription), compared with 9% receiving Asacol, 7 (250 mg) and 10% (500 mg) receiving Pentasa, 10% receiving balsalazide, and 10% receiving Dipentum.
Overall persistency with oral 5-ASA therapy was low. However, patients receiving once-daily Lialda had significantly higher persistency after 1 year of treatment than patients receiving other oral 5-ASA therapies.
Keywords5-aminosalicylic acid Mesalazine Mesalamine Persistency Ulcerative colitis Pharmacy database
Initial data analyses were undertaken by Michael Cheyne and Matthew Hauben who are employees of SDI and received funding from Shire Pharmaceuticals Inc., USA. Writing and editorial support was provided by Duncan Campbell of GeoMed and funded by Shire Pharmaceuticals Inc., USA.
Conflict of interest
Sunanda Kane has served as a consultant for and has received research support from Shire Pharmaceuticals Inc., USA. Michael Sumner, Dory Solomon, and Matt Jenkins are all employees of Shire Pharmaceuticals Inc., USA.
- 1.Lichtenstein GR, Rutgeerts P. The importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2009;16:338–346.Google Scholar
- 9.Kane S, De Vos M, Riley S, Frieri G, Mittmann U. Compliance issues in inflammatory bowel disease. Rev Gastroenterol Disord. 2005;5:101–106.Google Scholar
- 24.Esposito D, Wahl P, Daniel G, Stoto MA, Erder MH, Croghan TW. Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States. Clin Ther. 2009;31:644–656.PubMedCrossRefGoogle Scholar
- 30.Magowan SKS, Lange J. 5-ASA prescription refill rates of ulcerative colitis are independent of formulation and dosing regimens. Am J Gastroenterol. 2006;101:S447. (Abstract 1144).Google Scholar